Article Text

PDF
CASE REPORT
Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes
  1. Christine E Martinez,
  2. John B Allen,
  3. Frederick H Davidorf,
  4. Colleen M Cebulla
  1. Havener Eye Institute, Department of Ophthalmology and Visual Science, Ohio State University Wexner Medical Center, Columbus, Ohio, USA
  1. Correspondence to Dr Colleen M Cebulla, colleen.cebulla{at}osumc.edu

Summary

A 64-year-old man with type 2 diabetes mellitus and plaque psoriasis presented to the emergency room with 3 days of progressive right eye pain and decreased vision. After extensive workup and multidisciplinary team effort, the patient was diagnosed with and treated for unilateral endogenous methicillin-sensitive Staphylococcus aureus endophthalmitis, bacteraemia and osteomyelitis of the foot. The patient had been started on the interleukin 17 (IL-17) inhibitor secukinumab for his treatment-resistant plaque psoriasis 4 weeks prior to presentation. After treatment, his final vision was light perception and the foot infection resolved without sequelae. To our knowledge, this is the first reported case of both endogenous endophthalmitis and osteomyelitis associated with an IL-17 inhibitor.

  • Dermatology
  • Skin
  • Bone And Joint Infections
  • Ophthalmology
  • Safety
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors CM contributed to the drafting and editing of the manuscript. JA, CC and FD each contributed to the content and editing of the manuscript. Each of the authors participated in the medical care of the patient who is described in this case, including his surgical care. Each of the four authors reviewed and approved the final version of the manuscript.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.